Javascript must be enabled to continue!
Data from Aberrant Activation of Cell-Cycle–Related Kinases and the Potential Therapeutic Impact of PLK1 or CHEK1 Inhibition in Uterine Leiomyosarcoma
View through CrossRef
<div>AbstractPurpose:<p>Uterine leiomyosarcoma is among the most aggressive gynecological malignancies. No effective treatment strategies have been established. This study aimed to identify novel therapeutic targets for uterine leiomyosarcoma based on transcriptome analysis and assess the preclinical efficacy of novel drug candidates.</p>Experimental Design:<p>Transcriptome analysis was performed using fresh-frozen samples of six uterine leiomyosarcomas and three myomas. The Ingenuity Pathway Analysis (IPA) was used to identify potential therapeutic target genes for uterine leiomyosarcoma. Afterward, our results were validated using three independent datasets, including 40 uterine leiomyosarcomas. Then, the inhibitory effects of several selective inhibitors for the candidate genes were examined using SK-UT-1, SK-LMS-1, and SKN cell lines.</p>Results:<p>We identified 512 considerably dysregulated genes in uterine leiomyosarcoma compared with myoma. The IPA revealed that the function of several genes, including CHEK1 and PLK1, were predicted to be activated in uterine leiomyosarcoma. Through an <i>in vitro</i> drug screening, PLK1 or CHEK1 inhibitors (BI-2536 or prexasertib) were found to exert a superior anticancer effect against cell lines at low nanomolar concentrations and induce cell-cycle arrest. In SK-UT-1 tumor-bearing mice, BI-2536 monotherapy remarkably suppressed tumorigenicity. Moreover, the prexasertib and cisplatin combination therapy inhibited tumor proliferation and prolonged the time to tumor progression.</p>Conclusions:<p>We identified upregulated expressions of <i>PLK1</i> and <i>CHEK1</i>; their kinase activity was activated in uterine leiomyosarcoma. BI-2536 and prexasertib demonstrated a significant anticancer effect. Therefore, cell-cycle–related kinases may present a promising therapeutic strategy for the treatment of uterine leiomyosarcoma.</p></div>
American Association for Cancer Research (AACR)
Title: Data from Aberrant Activation of Cell-Cycle–Related Kinases and the Potential Therapeutic Impact of PLK1 or CHEK1 Inhibition in Uterine Leiomyosarcoma
Description:
<div>AbstractPurpose:<p>Uterine leiomyosarcoma is among the most aggressive gynecological malignancies.
No effective treatment strategies have been established.
This study aimed to identify novel therapeutic targets for uterine leiomyosarcoma based on transcriptome analysis and assess the preclinical efficacy of novel drug candidates.
</p>Experimental Design:<p>Transcriptome analysis was performed using fresh-frozen samples of six uterine leiomyosarcomas and three myomas.
The Ingenuity Pathway Analysis (IPA) was used to identify potential therapeutic target genes for uterine leiomyosarcoma.
Afterward, our results were validated using three independent datasets, including 40 uterine leiomyosarcomas.
Then, the inhibitory effects of several selective inhibitors for the candidate genes were examined using SK-UT-1, SK-LMS-1, and SKN cell lines.
</p>Results:<p>We identified 512 considerably dysregulated genes in uterine leiomyosarcoma compared with myoma.
The IPA revealed that the function of several genes, including CHEK1 and PLK1, were predicted to be activated in uterine leiomyosarcoma.
Through an <i>in vitro</i> drug screening, PLK1 or CHEK1 inhibitors (BI-2536 or prexasertib) were found to exert a superior anticancer effect against cell lines at low nanomolar concentrations and induce cell-cycle arrest.
In SK-UT-1 tumor-bearing mice, BI-2536 monotherapy remarkably suppressed tumorigenicity.
Moreover, the prexasertib and cisplatin combination therapy inhibited tumor proliferation and prolonged the time to tumor progression.
</p>Conclusions:<p>We identified upregulated expressions of <i>PLK1</i> and <i>CHEK1</i>; their kinase activity was activated in uterine leiomyosarcoma.
BI-2536 and prexasertib demonstrated a significant anticancer effect.
Therefore, cell-cycle–related kinases may present a promising therapeutic strategy for the treatment of uterine leiomyosarcoma.
</p></div>.
Related Results
Integrative transcriptomics analysis for uterine leiomyosarcoma identifies aberrant activation of cell cycle-dependent kinases and their potential therapeutic significance
Integrative transcriptomics analysis for uterine leiomyosarcoma identifies aberrant activation of cell cycle-dependent kinases and their potential therapeutic significance
Abstract
Purpose
Uterine leiomyosarcoma is among the most aggressive gynecological malignancies. No effective treatment strateg...
Abstract 3459: Dual targeting of BTK and PLK1 causes lethal synergistic effects in mantle cell lymphoma
Abstract 3459: Dual targeting of BTK and PLK1 causes lethal synergistic effects in mantle cell lymphoma
Abstract
Mantle cell lymphoma (MCL) is an incurable, aggressive B cell malignancy. Ibrutinib, an oral irreversible Bruton's tyrosine (BTK) inhibitor, was FDA-approve...
Abstract 1133: Plk1 phosphorylation of PTEN causes a tumor-promoting metabolic state
Abstract 1133: Plk1 phosphorylation of PTEN causes a tumor-promoting metabolic state
Abstract
One outcome of activation of the PI3K pathway is increased aerobic glycolysis, but the upstream signaling events that regulate the PI3K pathway, thus the Wa...
Possibilities of differential diagnosis of uterine leiomyosarcoma
Possibilities of differential diagnosis of uterine leiomyosarcoma
Uterine leiomyosarcoma is a rare malignant neoplasm consisting of smooth muscle cells, characterized by an aggressive course and poor prognosis.
Differential diagnosis of uterine ...
Uterine Myxoid Leiomyosarcoma with Stromal Chondroid Metaplasia: A Rare Case Report
Uterine Myxoid Leiomyosarcoma with Stromal Chondroid Metaplasia: A Rare Case Report
Background: Uterine leiomyosarcoma is a rare gynecological disease. Myxoid leiomyosarcoma (mLMS) is an aggressive and very uncommon type of leiomyosarcoma, with few cases reported ...
Uterine Myxoid Leiomyosarcoma with Stromal Chondroid Metaplasia: A Rare Case Report
Uterine Myxoid Leiomyosarcoma with Stromal Chondroid Metaplasia: A Rare Case Report
Background: Uterine leiomyosarcoma is a rare gynecological disease. Myxoid leiomyosarcoma (mLMS) is an aggressive and very uncommon type of leiomyosarcoma, with few cases reported ...
Pembrolizumab and Sarcoma: A meta-analysis
Pembrolizumab and Sarcoma: A meta-analysis
Abstract
Introduction: Pembrolizumab is a monoclonal antibody that promotes antitumor immunity. This study presents a systematic review and meta-analysis of the efficacy and safety...
The interrelationship between APC/C and Plk1 activities in centriole disengagement
The interrelationship between APC/C and Plk1 activities in centriole disengagement
Summary
Mother–daughter centriole disengagement, the necessary first step in centriole duplication, involves Plk1 activity in early mitosis and separase activity aft...

